Previous 10 | Next 10 |
ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for...
Aytu BioPharma ( NASDAQ: AYTU ) said it had received a written notification from the Nasdaq saying it had regained compliance with the minimum bid price requirement. The company said Nasdaq confirmed that for the ten consecutive business days, from January 6 to January 20, the clo...
ENGLEWOOD, CO / ACCESSWIRE / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that it received ...
ENGLEWOOD, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that Josh Disbrow...
Penny stocks can be a great way to make money, but they are also high-risk investments that can easily lead to significant losses. In order to be successful with penny stocks , it is important to be well-informed, disciplined, and patient. Today’s article looks at a few penny stock...
Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall ® Supply Disruption ENGLEWOOD, CO / ACCESSWIRE / January 10, 2023 / Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are curren...
Aytu BioPharma ( NASDAQ: AYTU ) announced a 1-for-20 reverse stock split of its outstanding common stock, effective on January 6, 2023. Beginning tomorrow, January 6, 2023, the Company's common stock will trade on a split-adjusted basis. The company's Board of Directors implem...
ENGLEWOOD, CO / ACCESSWIRE / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse...
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall ® XR Supply Disruption Adzenys XR-ODT is the Only FDA-Approved, Extended-Rel...
ENGLEWOOD, CO / ACCESSWIRE / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the C...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...